Press release – For immediate release – 5:45 pm CET
Median Technologies to Speak at the IASLC 2023 North America Conference on Lung Cancer (NACLC), Dec. 1-3, Chicago, IL, USA, with two Presentations.
- eyonis™ (formerly known as iBiopsy®) scientific poster presentation: End-to-End AI model for Nodule Detection and Characterization in Lung Cancer Screening: Performances and Subpopulation Analysis
- Imaging Lab scientific poster presentation: A CT Imaging Biomarker for CD8+ Lymphocytes Infiltration Stratification in Patients with Non-Small Cell Lung Cancer
- Median’s eyonis™ and Imaging Lab teams will attend the event and be available after poster sessions for presenting the latest advances of eyonis™ AI/ML tech based SaMD and the Imaging Lab developments.
Median Technologies (ALMDT) announced today that the Company will be presenting two scientific posters at the 2023 North America Conference on Lung Cancer (NACLC) being held in Chicago (Chicago Marriott Downtown Magnificent Mile), Il, USA, Dec. 1 – 3. The NACLC is organized by the International Association for the Study of Lung Cancer (IASLC), a global multidisciplinary association dedicated to eradication of all forms of lung cancers.
The Company will give two poster presentations on December 2nd from 5:40 to 6:55 pm CT.
Poster PP01.49: End to End AI model for Nodule Detection and Characterization in Lung Cancer Screening: Performances and Subpopulation Analysis
Poster PP01.44: A CT Imaging Biomarker for CD8+ Lymphocytes Infiltration Stratification in Patients with Non-Small Cell Lung Cancer
Median’s eyonis™ and Imaging Lab teams will attend the event and be available for presenting the latest advances of eyonis® AI/ML tech based SaMD and the Imaging Lab developments.
Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit